Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA4 | P22748 | 2/20 | 0.57 |
| ▸ | CA6 | P23280 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RARG | P13631 | 4/20 | 0.57 |
| ▸ | RARB | P10826 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654169 | 0.84 | RARB (0.71) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL384263 | 0.84 | RARB (0.71) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL1853155 | 0.84 | ESRRA (0.54) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL13653068 | 0.83 | RARB (0.51) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL18618101 | 0.82 | LCK (0.48) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL19658061 | 0.82 | POLB (0.57) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL850916 | 0.80 | POLB (0.57) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL5214177 | 0.80 | EPHX2 (0.49) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL30669213 | 0.80 | POLB (0.57) | POLBMEN1APEX1KMT2ACTDSP1 | |
| SCHEMBL1355563 | 0.80 | RARB (0.49) | POLBMEN1APEX1KMT2ACTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230296984-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230296984-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20210397090-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION AND METHOD FOR FORMING RESIST PATTERN USING THE SAME | NISSAN CHEMICAL CORPORATION (JP) | 2021-12-23 | — | — | US | disclosed |
| US-9884043-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884043-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170340610-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170340610-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME LLC | 2017-11-30 | — | — | US | disclosed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603838-B2 | RORgammaT inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-5261953-A | CONTAINING WATER SOLUBLE STABILIZER TO IMPROVE COLORFASTNESS | CIBA-GEIGY CORPORATION (US) | 1993-11-16 | — | — | US | disclosed |
| US-5089050-A | Phenol derivatives | CIBA-GEIGY CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| US-3985797-A | Hydroxylation of aromatic compounds | UOP INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3985796-A | Hydroxylation of aromatic compounds | UOP INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3931295-A | Hydroxylation of aromatic compounds | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340610-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | POLB 3551/4885MEN1 2510/4885APEX1 4828/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | POLB 427/4885MEN1 2785/4885APEX1 2280/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | POLB 2923/4885MEN1 2029/4885APEX1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.